Respiratory syncytial virus Novocastra
Respiratory syncytial virus (RSV) is the most important respiratory pathogen of childhood and is responsible for approximately 50 percent of all cases of bronchiolitis and 25 percent of all cases of pneumonia during the first few months of life. Approximately one percent of babies who develop an RSV infection between two and six months die, particularly those with congenital heart defects, bronchopulmonary dysplasia, low birth weight or immunodeficiency. The virus is also associated with significant lower respiratory disease in elderly and immunosuppressed individuals in whom mortality rates may be high. Multiple types and subtypes of RSV cocirculate in the population.
Product Specific Information
NCL-RSV3 is a cocktail of four antibodies. NCL-RSV3 does not cross-react with Parainfluenza virus types 1, 2, 3 and 4b, Adenovirus, Mumps virus, Measles virus, Influenza virus types A and B, Poliovirus types 1, 2 and 3, Coxsackie B4 virus, Echovirus 19, Varicella-zoster virus, Cytomegalovirus and Herpes simplex virus types 1 and 2.